PURE Bioscience, Inc. PURE
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.27% | 26.67% | 29.27% | 31.00% | 12.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.27% | 26.67% | 29.27% | 31.00% | 12.18% |
| Cost of Revenue | 10.34% | 24.31% | 24.58% | 21.52% | 10.85% |
| Gross Profit | 1.77% | 28.38% | 32.63% | 37.97% | 13.11% |
| SG&A Expenses | -5.58% | -10.20% | -13.85% | -17.63% | -18.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.63% | -3.32% | -6.02% | -9.62% | -12.17% |
| Operating Income | 8.32% | 25.59% | 29.42% | 33.57% | 27.44% |
| Income Before Tax | -3.50% | 21.89% | 30.29% | 34.20% | 28.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.50% | 21.89% | 30.29% | 34.20% | 28.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.50% | 21.89% | 30.29% | 34.20% | 28.39% |
| EBIT | 8.32% | 25.59% | 29.42% | 33.57% | 27.44% |
| EBITDA | 6.87% | 23.39% | 26.61% | 30.27% | 25.13% |
| EPS Basic | 0.93% | 22.13% | 30.58% | 34.68% | 28.57% |
| Normalized Basic EPS | 0.00% | 25.16% | 28.82% | 32.60% | 27.17% |
| EPS Diluted | 0.93% | 22.13% | 30.58% | 34.68% | 28.57% |
| Normalized Diluted EPS | 0.00% | 25.16% | 28.82% | 32.60% | 27.17% |
| Average Basic Shares Outstanding | 4.10% | -0.21% | 0.02% | 0.01% | 0.01% |
| Average Diluted Shares Outstanding | 4.10% | -0.21% | 0.02% | 0.01% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |